CEO of GSK Plays Down Its Role in FDA Effort
The CEO of GSK, Emma Walmsley, stated that the company has had a minimal role in the FDA's effort to approve a long-shelved drug for a condition associated with autism.
"We have no commercial interest, we have no scientific research, and we're not pursuing it. So it's just the administration at this stage."
The FDA requested that GSK update the prescribing information for its decades-old therapy leucovorin, which Walmsley described as "an administrative request" during a panel discussion at the STAT Summit.
GSK's role in the FDA's effort is limited to this administrative task, with no commercial or scientific interests involved.
Author's summary: GSK's CEO downplays company's role in FDA approval effort.
More News
- 1st Test: Noman Ali’s 10-for seals 93-run win for Pakistan over South Africa
- Southern Ky. city dealing with power outage
- 2 children, ages 9 and 10, charged with attempted murder, rape in brutal attack on 5-year-old girl, prosecutors say
- George Strait Sends Country Music Fans Into A Frenzy Teasing 2026 Announcement With Throwback Festival Poster
- Pope Leo gifted with "Proton" a purebred Arabian horse
- Olivia Nuzzi to spill secrets of RFK Jr. sexting scandal in new book
- Plasma resilience: Europe’s lifeline — and why we must strengthen it now
- Supreme Court appears to lean toward limiting Voting Rights Act's power
- California’s new AI law protects kids and sets a precedent
- Stellantis Moves Jeep Compass Production to Illinois, Raising Alarm for Canadian Auto Jobs - TechStory